GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

Szabolcs Bellyei, Andrew V Schally, Marta Zarandi, Jozsef L. Varga, Irving Vidaurre, Eva Pozsgai

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We investigated the effect of a GHRH antagonist, MIA-602. on the metastatic cascade in vitro of three human cancers, DBTRG-05 glioblastoma, MDA-MB-468 estrogen-independent breast, and ES-2 clear cell ovarian cancer. GHRH receptors and their main splice variant, SV1 were detected on all three cell lines. After treatment with MIA-602, the cell viability decreased significantly, significant inhibition of cell invasion was observed and the release of MMPs was significantly decreased. The attachment of cancer cells to fibronectin and matrigel was severely hindered. Wound-healing experiments demonstrated a reduced cellular motility in all three cell lines. The upregulation of caveolin-1 and E-cadherin,. and the. powerful downregulation of NF-κB and β-catenin was detected. Our study suggests that the clinical application of highly potent GHRH antagonists in cancer therapy would be desirable since they inhibit proliferation and metastasis development as well.

Original languageEnglish
Pages (from-to)31-40
Number of pages10
JournalCancer Letters
Volume293
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Cell Line
Caveolin 1
Catenins
Neoplasms
Cadherins
Glioblastoma
Matrix Metalloproteinases
Fibronectins
Ovarian Neoplasms
Wound Healing
Cell Survival
Estrogens
Breast
Up-Regulation
Down-Regulation
Neoplasm Metastasis
In Vitro Techniques
GHRH(1-29)NH2, (PhAc-Ada)(0)-Tyr(1), Arg(2), Fpa(5,6), Ala(8), Har(9), Tyr(Me)(10), His(11), Orn(12,) Abu(15), His(20), Orn(21), Nle(27), Arg(28), Har(29)-
Therapeutics
Clinical Studies

Keywords

  • GHRH antagonist
  • Invasion
  • Metastasis
  • MMP
  • NF-κB

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. / Bellyei, Szabolcs; Schally, Andrew V; Zarandi, Marta; Varga, Jozsef L.; Vidaurre, Irving; Pozsgai, Eva.

In: Cancer Letters, Vol. 293, No. 1, 01.07.2010, p. 31-40.

Research output: Contribution to journalArticle

Bellyei, Szabolcs ; Schally, Andrew V ; Zarandi, Marta ; Varga, Jozsef L. ; Vidaurre, Irving ; Pozsgai, Eva. / GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. In: Cancer Letters. 2010 ; Vol. 293, No. 1. pp. 31-40.
@article{013fde141d81499682b3de48bf5a1b35,
title = "GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro",
abstract = "We investigated the effect of a GHRH antagonist, MIA-602. on the metastatic cascade in vitro of three human cancers, DBTRG-05 glioblastoma, MDA-MB-468 estrogen-independent breast, and ES-2 clear cell ovarian cancer. GHRH receptors and their main splice variant, SV1 were detected on all three cell lines. After treatment with MIA-602, the cell viability decreased significantly, significant inhibition of cell invasion was observed and the release of MMPs was significantly decreased. The attachment of cancer cells to fibronectin and matrigel was severely hindered. Wound-healing experiments demonstrated a reduced cellular motility in all three cell lines. The upregulation of caveolin-1 and E-cadherin,. and the. powerful downregulation of NF-κB and β-catenin was detected. Our study suggests that the clinical application of highly potent GHRH antagonists in cancer therapy would be desirable since they inhibit proliferation and metastasis development as well.",
keywords = "GHRH antagonist, Invasion, Metastasis, MMP, NF-κB",
author = "Szabolcs Bellyei and Schally, {Andrew V} and Marta Zarandi and Varga, {Jozsef L.} and Irving Vidaurre and Eva Pozsgai",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.canlet.2009.12.014",
language = "English",
volume = "293",
pages = "31--40",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

AU - Bellyei, Szabolcs

AU - Schally, Andrew V

AU - Zarandi, Marta

AU - Varga, Jozsef L.

AU - Vidaurre, Irving

AU - Pozsgai, Eva

PY - 2010/7/1

Y1 - 2010/7/1

N2 - We investigated the effect of a GHRH antagonist, MIA-602. on the metastatic cascade in vitro of three human cancers, DBTRG-05 glioblastoma, MDA-MB-468 estrogen-independent breast, and ES-2 clear cell ovarian cancer. GHRH receptors and their main splice variant, SV1 were detected on all three cell lines. After treatment with MIA-602, the cell viability decreased significantly, significant inhibition of cell invasion was observed and the release of MMPs was significantly decreased. The attachment of cancer cells to fibronectin and matrigel was severely hindered. Wound-healing experiments demonstrated a reduced cellular motility in all three cell lines. The upregulation of caveolin-1 and E-cadherin,. and the. powerful downregulation of NF-κB and β-catenin was detected. Our study suggests that the clinical application of highly potent GHRH antagonists in cancer therapy would be desirable since they inhibit proliferation and metastasis development as well.

AB - We investigated the effect of a GHRH antagonist, MIA-602. on the metastatic cascade in vitro of three human cancers, DBTRG-05 glioblastoma, MDA-MB-468 estrogen-independent breast, and ES-2 clear cell ovarian cancer. GHRH receptors and their main splice variant, SV1 were detected on all three cell lines. After treatment with MIA-602, the cell viability decreased significantly, significant inhibition of cell invasion was observed and the release of MMPs was significantly decreased. The attachment of cancer cells to fibronectin and matrigel was severely hindered. Wound-healing experiments demonstrated a reduced cellular motility in all three cell lines. The upregulation of caveolin-1 and E-cadherin,. and the. powerful downregulation of NF-κB and β-catenin was detected. Our study suggests that the clinical application of highly potent GHRH antagonists in cancer therapy would be desirable since they inhibit proliferation and metastasis development as well.

KW - GHRH antagonist

KW - Invasion

KW - Metastasis

KW - MMP

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=77952428957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952428957&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2009.12.014

DO - 10.1016/j.canlet.2009.12.014

M3 - Article

C2 - 20064686

AN - SCOPUS:77952428957

VL - 293

SP - 31

EP - 40

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -